Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic leukemia (CLL). Characteristically, ibrutinib causes CLL cell redistribution from tissue sites into the peripheral blood during the initial weeks of therapy. To better characteri...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Wodarz, Dominik, Garg, Naveen, Komarova, Natalia L., Benjamini, Ohad, Keating, Michael J., Wierda, William G., Kantarjian, Hagop, James, Danelle, O’Brien, Susan, Burger, Jan A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2014
Aiheet:
Lymphoid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123432/
https://ncbi.nlm.nih.gov/pubmed/24829205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-554220
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia